A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | MicrobiomeTrials← Back to trialsNCT06907875
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-08Est. Completion: 2027-07-07
Enrollment target: 12 participants Locations- David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
- Rare Disease Research, Atlanta, Georgia, United States
- Kennedy Krieger Institute, Center for Genetic Muscle Disorders, Baltimore, Maryland, United States
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
- Utah Program for Inherited Neuromuscular Disorders - University of Utah, Salt Lake City, Utah, United States
- Royal Alfred Hospital, Sydney, New South Wales, Australia
- Pacific Clinical Research Network, Auckland, New Zealand, New Zealand
Other microbiome trials you might be interested in
Facioscapulohumeral Muscular DystrophyFSHDFSHD - Facioscapulohumeral Muscular DystrophyFSHD1FSHD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Facioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral DystrophyFacio-Scapulo-Humeral DystrophyFacioscapulohumeral Muscular Dystrophy 2Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)FSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular Dystrophy
Landouzy-Dejerine Syndrome
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 102…
Orange, United StatesEst. completion May 2028
FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral MuscularFacioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral Muscular Dystrophy 2Facio-Scapulo-Humeral DystrophyAtrophy, FacioscapulohumeralAtrophies, FacioscapulohumeralFacioscapulohumeral AtrophyMuscular DystrophiesMuscular Dystrophy, FacioscapulohumeralFSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyDystrophies, Landouzy-DejerineDystrophy, Landouzy-DejerineLandouzy-Dejerine SyndromeMuscular Dystrophy, Landouzy DejerineProgressive Muscular DystrophyFSH
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, …
Los Angeles, United StatesCompleted Mar 18, 2026